JPWO2020236979A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020236979A5 JPWO2020236979A5 JP2021568854A JP2021568854A JPWO2020236979A5 JP WO2020236979 A5 JPWO2020236979 A5 JP WO2020236979A5 JP 2021568854 A JP2021568854 A JP 2021568854A JP 2021568854 A JP2021568854 A JP 2021568854A JP WO2020236979 A5 JPWO2020236979 A5 JP WO2020236979A5
- Authority
- JP
- Japan
- Prior art keywords
- microbial composition
- subject
- use according
- liver
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 54
- 230000000813 microbial effect Effects 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 32
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 27
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 27
- 206010067125 Liver injury Diseases 0.000 claims description 15
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 14
- 208000019423 liver disease Diseases 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 10
- 231100000234 hepatic damage Toxicity 0.000 claims description 9
- 230000008818 liver damage Effects 0.000 claims description 9
- 102000003929 Transaminases Human genes 0.000 claims description 8
- 108090000340 Transaminases Proteins 0.000 claims description 8
- 125000001980 alanyl group Chemical group 0.000 claims description 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 7
- 231100000753 hepatic injury Toxicity 0.000 claims description 6
- 241000702462 Akkermansia muciniphila Species 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- 241000193454 Clostridium beijerinckii Species 0.000 claims description 4
- 241000194031 Enterococcus faecium Species 0.000 claims description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000002091 elastography Methods 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 241000193171 Clostridium butyricum Species 0.000 claims description 3
- 206010072268 Drug-induced liver injury Diseases 0.000 claims description 3
- 241000186394 Eubacterium Species 0.000 claims description 3
- 206010019851 Hepatotoxicity Diseases 0.000 claims description 3
- 241000985249 [Clostridium] indolis Species 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 231100000304 hepatotoxicity Toxicity 0.000 claims description 3
- 230000007686 hepatotoxicity Effects 0.000 claims description 3
- MXBCYQUALCBQIJ-RYVPXURESA-N (8s,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 MXBCYQUALCBQIJ-RYVPXURESA-N 0.000 claims description 2
- 241001430193 Absiella dolichum Species 0.000 claims description 2
- 241001580965 Anaerofustis stercorihominis Species 0.000 claims description 2
- 241001505572 Anaerostipes caccae Species 0.000 claims description 2
- 241001584951 Anaerostipes hadrus Species 0.000 claims description 2
- 241000428313 Anaerotruncus colihominis Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000123777 Blautia obeum Species 0.000 claims description 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 2
- 241000193401 Clostridium acetobutylicum Species 0.000 claims description 2
- 241000193470 Clostridium sporogenes Species 0.000 claims description 2
- 241000193449 Clostridium tetani Species 0.000 claims description 2
- 241001464948 Coprococcus Species 0.000 claims description 2
- 241001464949 Coprococcus eutactus Species 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 241000605980 Faecalibacterium prausnitzii Species 0.000 claims description 2
- 241000605896 Fibrobacter succinogenes Species 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 241001134569 Flavonifractor plautii Species 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 2
- 240000001929 Lactobacillus brevis Species 0.000 claims description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 2
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 2
- 241001468191 Lactobacillus kefiri Species 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 241000266823 Oscillospira guilliermondii Species 0.000 claims description 2
- 241000605947 Roseburia Species 0.000 claims description 2
- 241000605944 Roseburia cecicola Species 0.000 claims description 2
- 241000872832 Roseburia hominis Species 0.000 claims description 2
- 241000398180 Roseburia intestinalis Species 0.000 claims description 2
- 241001394655 Roseburia inulinivorans Species 0.000 claims description 2
- 241000192026 Ruminococcus flavefaciens Species 0.000 claims description 2
- 235000014962 Streptococcus cremoris Nutrition 0.000 claims description 2
- 241000960363 Streptococcus infantis Species 0.000 claims description 2
- 241000194019 Streptococcus mutans Species 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 241000193458 [Clostridium] aminophilum Species 0.000 claims description 2
- 241001509494 [Clostridium] colinum Species 0.000 claims description 2
- 241001531188 [Eubacterium] rectale Species 0.000 claims description 2
- 241001464867 [Ruminococcus] gnavus Species 0.000 claims description 2
- 238000002126 acoustic radiation force impulse imaging Methods 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002099 shear wave elastography Methods 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- 241000186604 Lactobacillus reuteri Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 229940001882 lactobacillus reuteri Drugs 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 241001531197 [Eubacterium] hallii Species 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- -1 gummy Substances 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 1
- 241001531192 Eubacterium ventriosum Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962850773P | 2019-05-21 | 2019-05-21 | |
| US62/850,773 | 2019-05-21 | ||
| PCT/US2020/033870 WO2020236979A1 (en) | 2019-05-21 | 2020-05-20 | Methods and compositions for treating liver disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533672A JP2022533672A (ja) | 2022-07-25 |
| JPWO2020236979A5 true JPWO2020236979A5 (https=) | 2023-05-25 |
| JP2022533672A5 JP2022533672A5 (https=) | 2023-05-25 |
Family
ID=73458208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568854A Pending JP2022533672A (ja) | 2019-05-21 | 2020-05-20 | 肝障害を処置するための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220211780A1 (https=) |
| EP (1) | EP3973047A4 (https=) |
| JP (1) | JP2022533672A (https=) |
| KR (1) | KR20220011683A (https=) |
| CN (1) | CN113993529A (https=) |
| AU (1) | AU2020278703A1 (https=) |
| CA (1) | CA3140096A1 (https=) |
| SG (1) | SG11202112515RA (https=) |
| WO (1) | WO2020236979A1 (https=) |
| ZA (1) | ZA202110111B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| SG11202112515RA (en) * | 2019-05-21 | 2021-12-30 | Pendulum Therapeutics Inc | Methods and compositions for treating liver disorders |
| NL2030011B1 (en) * | 2021-12-03 | 2023-06-20 | Caelus Pharmaceuticals B V | Prevention or treatment of hepatic steatosis |
| EP4467148A4 (en) * | 2022-01-20 | 2025-04-23 | Korea Institute of Science and Technology | Composition for prevention, amelioration or treatment of non-alcoholic fatty liver disease, comprising extracellular vesicles derived from roseburia spp. or bifidobacterium spp |
| CN117599092B (zh) * | 2024-01-23 | 2024-04-26 | 南方医科大学南方医院 | 生孢梭菌在制备预防和/或治疗肝脏疾病的药物中的应用 |
| CN118526527A (zh) * | 2024-03-19 | 2024-08-23 | 华中科技大学同济医学院附属协和医院 | 益生菌混合液在制备预防或治疗apap诱导肝损伤药物中的应用 |
| KR102679094B1 (ko) * | 2024-04-24 | 2024-06-27 | 충남대학교 산학협력단 | 항비만 효능을 지닌 한국인 마이크로바이옴 유래 클로스트리디움 부티리쿰 균주 및 이의 용도 |
| CN119639633A (zh) * | 2025-02-18 | 2025-03-18 | 杭州师范大学附属医院(杭州市第二人民医院) | 一种治疗非酒精性脂肪肝的酵母菌益生菌复合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201903823QA (en) * | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3402475B1 (en) * | 2016-01-11 | 2021-10-20 | Egetis Therapeutics AB | Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions |
| AU2017370681A1 (en) * | 2016-12-06 | 2019-06-27 | Pendulum Therapeutics, Inc. | Methods and compositions relating to isolated and purified microbes |
| CN111372596A (zh) * | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| AU2018341734B2 (en) * | 2017-09-28 | 2022-02-03 | Kobiolabs, Inc. | Composition for diagnosis and treatment of alcoholic liver disease, using change in short-chain fatty acid producing gut bacterial community |
| CA3113684A1 (en) * | 2018-09-24 | 2020-04-02 | Pendulum Therapeutics, Inc. | Microbial compositions and methods of use |
| SG11202112515RA (en) * | 2019-05-21 | 2021-12-30 | Pendulum Therapeutics Inc | Methods and compositions for treating liver disorders |
-
2020
- 2020-05-20 SG SG11202112515RA patent/SG11202112515RA/en unknown
- 2020-05-20 WO PCT/US2020/033870 patent/WO2020236979A1/en not_active Ceased
- 2020-05-20 CN CN202080043100.6A patent/CN113993529A/zh active Pending
- 2020-05-20 KR KR1020217041642A patent/KR20220011683A/ko not_active Withdrawn
- 2020-05-20 JP JP2021568854A patent/JP2022533672A/ja active Pending
- 2020-05-20 AU AU2020278703A patent/AU2020278703A1/en not_active Abandoned
- 2020-05-20 EP EP20809882.2A patent/EP3973047A4/en not_active Withdrawn
- 2020-05-20 US US17/610,398 patent/US20220211780A1/en not_active Abandoned
- 2020-05-20 CA CA3140096A patent/CA3140096A1/en active Pending
-
2021
- 2021-12-07 ZA ZA2021/10111A patent/ZA202110111B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Byakika et al. | A review of criteria and methods for evaluating the probiotic potential of microorganisms | |
| Derrien et al. | Fate, activity, and impact of ingested bacteria within the human gut microbiota | |
| Bozzi Cionci et al. | Therapeutic microbiology: the role of Bifidobacterium breve as food supplement for the prevention/treatment of paediatric diseases | |
| Venturi et al. | Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis | |
| JP2024003162A (ja) | クロストリジウム・ディフィシル感染症の治療における新たな使用 | |
| Oliveira et al. | Use of lactulose as prebiotic and its influence on the growth, acidification profile and viable counts of different probiotics in fermented skim milk | |
| Enck et al. | Dysbiosis in functional bowel disorders | |
| Rosenfeldt et al. | Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea | |
| Ebel et al. | Impact of probiotics on risk factors for cardiovascular diseases. A review | |
| Saxelin et al. | Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese | |
| Alvaro et al. | Composition and metabolism of the intestinal microbiota in consumers and non-consumers of yogurt | |
| US11896631B2 (en) | Probiotics for use in the treatment of diverticulosis and diverticular disease | |
| Sánchez et al. | Adaptation of bifidobacteria to the gastrointestinal tract and functional consequences | |
| Liu et al. | Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases | |
| US20220211780A1 (en) | Methods And Compositions For Treating Liver Disorders | |
| Marteau et al. | Probiotics and health: new facts and ideas | |
| JP2019516775A5 (https=) | ||
| RU2011150201A (ru) | Кратковременная высокотемпературная обработка для микробных препаратов с противовоспалительными свойствами | |
| US20180177833A1 (en) | Bifidobacteria as probiotic foundation species of gut microbiota | |
| Kitazawa et al. | Probiotics: immunobiotics and immunogenics | |
| Sanders | Summary of probiotic activities of Bifidobacterium lactis HN019 | |
| BR112018074355A2 (pt) | composição de probióticos e enzimas digestivas e método de preparação e uso do mesmo | |
| JPWO2020236979A5 (https=) | ||
| Lebeer et al. | Topical cream with live lactobacilli modulates the skin microbiome and reduce acne symptoms | |
| Yazid et al. | Antimicrobial susceptibility of bifidobacteria |